Insulin Aspart
Metabolic / DiabetesAlso known as: NovoLog, Fiasp, NovoRapid
Mechanism
A rapid-acting mealtime insulin — very similar to lispro but with a different amino acid change. One proline is swapped for aspartic acid, which adds a negative charge that pushes insulin molecules apart so they absorb faster. The newer Fiasp version adds vitamin B3 (niacinamide) to speed things up even more. Widely used in insulin pumps and for mealtime bolus dosing.
Technical detail
Rapid-acting recombinant insulin analog produced in S. cerevisiae. Single substitution: Pro-B28 → Asp (aspartic acid). The negatively charged Asp residue introduces charge repulsion that destabilizes dimer interface, accelerating hexamer → monomer dissociation at injection site. PK: onset 10-20 min, peak 40-50 min, duration 3-5 hours. Fiasp (faster-acting insulin aspart): same molecule co-formulated with niacinamide (vitamin B3, 170 mM) and L-arginine (as stabilizer). Niacinamide increases local vasodilation and vascular permeability at injection site, accelerating initial absorption rate. Result: 5 min earlier onset and ~2x higher insulin exposure in first 30 min vs. NovoLog. Insulin receptor binding affinity equivalent to human insulin. Approved for use in both SC injection and continuous subcutaneous insulin infusion (CSII/pump) systems. NovoRapid is the ex-US brand name (same molecule as NovoLog).
Effects
METABOLIC SYSTEM: Insulin aspart is a rapid-acting insulin analog created by substituting proline at position B28 with aspartic acid (Asp) [pharmacological]. This single amino acid change disrupts the self-association tendency of insulin molecules — native insulin forms hexamers that must dissociate to monomers before absorption from subcutaneous tissue. The B28 Asp substitution introduces charge repulsion that destabilizes hexamers, promoting faster dissociation to monomers at the injection site [crystallographic, pharmacokinetic]. PHARMACOKINETICS (NOVORAPID/NOVOLOG): Onset: 10-20 minutes (vs. 30-60 minutes for regular human insulin). Peak: 1-3 hours. Duration: 3-5 hours. This faster profile better matches postprandial glucose excursions, reducing post-meal hyperglycemia and late hypoglycemia [RCT]. FIASP (FASTER ASPART): Fiasp adds two excipients to insulin aspart: niacinamide (vitamin B3, 170 mM) which increases local vasodilation and vascular permeability at the injection site, accelerating absorption by ~5-10 minutes, and L-arginine as a stabilizer [pharmacokinetic]. Onset: 5-15 minutes (approximately 5 minutes faster than NovoLog). Earlier insulin exposure: 2x greater exposure in first 30 minutes compared to NovoLog [pharmacokinetic studies]. Clinical benefit: further reduction in post-meal glucose excursions, particularly the 1-hour postprandial peak [RCT — onset trials]. GLYCEMIC CONTROL: In type 1 diabetes, insulin aspart achieves HbA1c reductions of 0.1-0.2% greater than regular human insulin with less postprandial hyperglycemia and reduced late hypoglycemia [RCT, meta-analyses]. In type 2 diabetes, similar HbA1c reduction with improved mealtime flexibility. INSULIN PUMP COMPATIBILITY: Insulin aspart is one of the most widely used insulins in continuous subcutaneous insulin infusion (CSII) pumps — the rapid absorption profile is ideal for pump therapy, and aspart has demonstrated stability in pump reservoirs for up to 6-7 days at body temperature [clinical, stability studies]. Fiasp is also approved for pump use but some users report more frequent infusion set occlusions (potentially due to niacinamide-related effects on catheter materials) [clinical observation, post-marketing].
Practitioner Guide
ADMINISTRATION: Subcutaneous injection or insulin pump infusion. NovoLog/NovoRapid: inject 5-10 minutes before meals. Fiasp: inject at the start of a meal or up to 20 minutes after starting a meal (the key advantage — greater dosing flexibility). Can also be given IV in hospital settings for DKA management (only rapid-acting analog approved for IV use). DOSING: Individualized based on patient needs. General starting dose for mealtime insulin: 0.1 units/kg/meal or total daily insulin divided ~50/50 basal-bolus with bolus split across meals. Insulin-to-carb ratio: typically start at 1:10-1:15 (1 unit per 10-15g carbohydrate), adjust based on blood glucose monitoring. Correction factor: 1 unit lowers blood glucose by approximately 50 mg/dL in type 1 (varies widely — use the 1800 rule: 1800 ÷ total daily dose = correction factor in mg/dL). PUMP THERAPY: Set basal rates, bolus calculator with insulin-to-carb ratio and correction factor. Change infusion set every 2-3 days. Monitor for infusion site issues (lipohypertrophy, occlusion). Fiasp in pumps: may need more frequent set changes in some patients; monitor for unexplained glucose rises that could indicate occlusion. INJECTION TECHNIQUE: SC injection into abdomen (fastest absorption), thigh, or upper arm. Rotate injection sites within the same region — lipohypertrophy from repeated same-site injection causes erratic absorption and poor glycemic control. Use 4-5 mm pen needles (shorter needles reduce IM injection risk). No need to pinch skin with short needles. SWITCHING FROM REGULAR INSULIN: Convert unit-for-unit. Adjust timing: NovoLog 5-10 min pre-meal (vs. 30 min for regular). Fiasp at meal start. Monitor for 1-2 weeks and adjust ratios. HYPOGLYCEMIA MANAGEMENT: Treat glucose <70 mg/dL with 15g fast-acting carbohydrates, recheck in 15 minutes. Severe hypoglycemia: glucagon 1 mg IM/SC or nasal glucagon. Educate patients on symptom recognition. STORAGE: Unopened: refrigerate (2-8°C). In-use: room temperature up to 30°C for 28 days (NovoLog) or 21 days (Fiasp). Do not freeze. Protect from direct heat and light. Pumps: change reservoir every 6 days max (aspart stability limit).
Research Summary
TIER 1: Multiple Phase III RCTs establishing insulin aspart efficacy — non-inferior to regular human insulin with improved postprandial glucose control and patient satisfaction. Onset trials (onset 1-8): Fiasp vs. NovoLog across T1D and T2D populations, demonstrating faster onset and improved 1-hour postprandial glucose with similar HbA1c and safety. FDA-approved: NovoLog (2000), Fiasp (2017). Extensive real-world data from millions of patients over 25+ years. TIER 2: Meta-analyses of rapid-acting insulin analogs (aspart, lispro, glulisine) — generally equivalent efficacy with minor pharmacokinetic differences (Defined et al., Cochrane reviews). Pharmacokinetic characterization of niacinamide's mechanism in Fiasp (Heise et al., 2015). Pump compatibility and stability studies. Cost-effectiveness analyses (biosimilar insulin aspart now available — significant cost reduction). Reviews comparing Fiasp to other ultra-rapid insulins (URLi/insulin lispro-aabc). TIER 3: Large diabetes registry data (T1D Exchange, DPSG, Swedish NDR) showing real-world outcomes. Pump user community experience with Fiasp (mixed — some love the speed, some report more occlusions). Pediatric endocrinology practice data. KEY FINDINGS: Insulin aspart is a mature, well-validated rapid-acting insulin that has been a mealtime standard for over two decades. Fiasp's niacinamide innovation is a genuine pharmacokinetic improvement, though the clinical benefit over standard aspart is incremental (~0.1% HbA1c, modest postprandial improvement). The pump occlusion concern with Fiasp is real but manageable. Biosimilar availability is improving access. GAPS: Long-term comparative data Fiasp vs. ultra-rapid lispro (Lyumjev). Optimal use with automated insulin delivery (AID) systems still being refined. Fiasp pump occlusion issue not fully resolved. ACTIVE TRIALS: Integration with closed-loop/AID systems. Fiasp in pediatric populations. Biosimilar aspart outcome studies.